Janssen, Jeroen J. W. M.

2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

Apperley, J. F., Milojkovic, D., Cross, N. C. P., Hjorth-Hansen, H., Hochhaus, A., Kantarjian, H., Lipton, J. H., Malhotra, H., Niederwieser, D., Radich, J., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 139

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

Ector, G. I., Westerweel, P. E., Hermens, R. P., Braspenning, K. A., Heeren, B. C., Vinck, O. M., de Jong, J. J., Janssen, J. J., & Blijlevens, N. M. (2020) · Journal of Medical Internet Research

Mobile Health and mHealth ApplicationsInnovative Human-Technology Interaction

Cited by 57

Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results

Cortes, J. E., Sasaki, K., Kim, D.-W., Hughes, T. P., Etienne, G., Mauro, M. J., Hochhaus, A., Lang, F., Heinrich, M. C., Breccia, M., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 56

Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Mauro, M. J., Hughes, T. P., Kim, D.-W., Rea, D., Cortes, J. E., Hochhaus, A., Sasaki, K., Breccia, M., Talpaz, M., Ottmann, O., et al. (2023) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 53

Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling

Boons, C. C. L. M., Timmers, L., Janssen, J. J. W. M., Swart, E. L., Hugtenburg, J. G., & Hendrikse, N. H. (2019) · European Journal of Clinical Pharmacology

Biosimilars and Bioanalytical MethodsClinical Laboratory Practices and Quality Control

Cited by 36

The evolution of the loss of life expectancy in patients with chronic myeloid leukaemia: a population‐based study in the Netherlands, 1989–2018

Maas, C. C. H. M., van Klaveren, D., Ector, G. I. C. G., Posthuma, E. F. M., Visser, O., Westerweel, P. E., Janssen, J. J. W. M., Blijlevens, N. M. A., & Dinmohamed, A. G. (2022) · British Journal of Haematology

Chronic Myeloid Leukemia TreatmentsMultiple and Secondary Primary Cancers

Cited by 31

Treatment patterns and clinical outcomes of asciminib in a real-world multiresistant chronic myeloid leukemia patient population

Kockerols, C. C. B., Janssen, J. J. W. M., Blijlevens, N. M. A., Klein, S. K., Van Hussen-Daenen, L. G. M., Van Gorkom, G. G. Y., Smit, W. M., Van Balen, P., Biemond, B. J., Cruijsen, M. J., et al. (2022) · Haematologica

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 22

Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial

Flygt, H., Söderlund, S., Richter, J., Saussele, S., Koskenvesa, P., Stenke, L., Mustjoki, S., Dimitrijevic, A., Stentoft, J., Majeed, W., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results

Cortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 16

Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Efficace, F., Mahon, F.-X., Richter, J., Piciocchi, A., Cipriani, M., Nicolini, F. E., Mayer, J., Zackova, D., Janssen, J. J. W. M., Panayiotidis, P., et al. (2024) · Leukemia

Chronic Myeloid Leukemia TreatmentsCancer survivorship and care

Cited by 15

Prediction of sustained remission after tyrosine kinase inhibitor discontinuation with BCR::ABL1 digital PCR in chronic myeloid leukemia patients

Kockerols, C., Valk, P. J. M., Janssen, J. J. W. M., Hogenbirk, P., Cornelissen, J. J., Saussele, S., Spiess, B., Perusini, M. A., Kim, D., & Westerweel, P. E. (2024) · European Journal of Haematology

Chronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research

Cited by 8